Share:
DIOSynVax was founded in 2017 by Professor Jonathan Heeney with the objective to radically alter the way vaccine antigens are designed.
Historically, the creation of an effective new vaccine has required years of work and hundreds of millions of pounds. DIOSynVax uses a multi-step vaccine platform technology that speeds up the process by customising vaccine antigen design to maximise the protection that vaccines can provide worldwide against existing and future viruses. Their innovative technology platform was developed to target certain vulnerabilities within the genetic sequence of related viruses, resulting in more effective, next generation vaccines.
Since 2019, DIOSynVax has secured multiple grants from a variety of organisations, including Innovate UK and CEPI (Coalition for Epidemic Preparedness Innovations) to further fuel their research and support the path to commercialisation for their novel vaccines. The DIOSynVax pipeline includes vaccine candidates for haemorrhagic fever, influenza, and coronaviruses, the latter of which is currently in clinical trials.